The Quiet Room Part 1

Chapter 93: The Quiet Room Part 1 The retrieval form looked harmless until Catherine Marsh reached the field marked Justification. Leah kept her cursor there, blinking over the white box, while the rest of the thirty-fourth floor went on breathing around her: phones murmuring, keyboards tapping, Priya's voice carrying briefly from a glass conference room. One wrong noun would leave a trail to Isabella Voss. One honest request would tell Martha Thorne exactly which door Catherine Marsh wanted opened. She deleted the first sentence before she finished it. Pre-2015 board minutes was too broad. Voss was impossible. Foundation transfers would be suicide. Even Costa Holdings could be dangerous if she sounded like an investigator instead of a junior analyst trying to complete David Choi's healthcare assignment. The ThorneVault retrieval module offered no comfort. It stated, in plain gray type, that all physical archive requests were logged and audited. Every employee name, date range, department, and purpose would be visible to records management, security, and anyone senior enough to ask. Leah imagined Martha's office receiving a neat report: Catherine Marsh, eight days inside the company, requesting old records no new analyst should need. She moved her hand from the trackpad and made herself breathe once. Four days at Thorne Group had given Catherine a rhythm convincing enough to survive casual observation. She arrived at 8:45, logged into ThorneVault by nine, worked on Costa's healthcare competitive landscape, ate lunch alone with a book open beside her tray, and spent afternoons turning real analysis into useful cover. Priya had approved her preliminary framework. David had stopped at her cubicle to ask whether she needed resources. The neighbors knew her name, not her history. No one had a reason to look deeper unless she gave them one. Leah pulled the retrieval form back into focus and filled it with the most boring version of danger she could invent: board minutes and acquisition due diligence reports, 2012-2015, Corporate Strategy / Costa Holdings. In the justification box, she wrote that the healthcare competitive landscape analysis required historical context for Costa Holdings' acquisition strategy before 2015, and that understanding the company's earlier portfolio would inform the forward-looking analysis requested by David Choi. The language was dull enough to be safe. It gave David's assignment institutional cover, placed the request inside Catherine's assigned healthcare work, and avoided every word that mattered. No Voss. No Foundation. No Martha. No 245 East 54th. Just a junior analyst being annoyingly thorough. She read it twice, then submitted before caution could become paralysis. The confirmation arrived in less than ten seconds: REQ-2024-0347 had been received, estimated processing time five to seven business days, with notification promised when the documents were available for review in the Research Room on the thirty-sixth floor. Leah kept her face still while something sharp and bright moved through her chest. It was not the records room, and it was not level-three clearance. It was a visitor pass to a controlled room where retrieved files could be reviewed under supervision. That was still enough to put Catherine Marsh on the thirty-sixth floor. It would let her observe badge protocols, hallway layout, sightlines, and the people who controlled the archive. Most importantly, it might put her within speaking distance of Geraldine Hoffman, twenty-eight years in records management, the woman who knew where old documents had gone after 245 East 54th was emptied. The door was not open, but the lock had admitted it existed. Leah closed the confirmation email, copied the request number into a clean work note, and returned to the healthcare deck. Catherine Marsh would not smile at a retrieval number. Catherine Marsh would notice the response, file it, and continue building page twelve of a Costa diagnostics analysis as if nothing in her life depended on it. At two, Priya called the weekly Market Analysis meeting. Eight analysts gathered in Conference Room A with notebooks, laptops, and the kind of guarded boredom people used to survive recurring meetings. Leah took a chair near the back. She did not need to be invisible today. She needed to be present in a way no one would remember. Priya moved through deadlines, resource conflicts, and an update on David's review calendar. Catherine's healthcare analysis received one sentence: on track, preliminary findings summary due next week. Leah nodded once, made a note, and let the agenda pass over her. Then Priya turned a page she had not mentioned at the beginning. "One more item. The executive floor has requested a briefing on the Costa Holdings healthcare portfolio. David will present, and he wants supporting analysis from this unit. I need two people to help prepare the materials." Several hands went up. Leah lifted hers after Marcus from the medical device segment and before the silence could make her abstention noticeable. Priya scanned the room. "Marcus, you take medical devices. Catherine, clinical diagnostics and pharmaceuticals. I'll send the briefing format this afternoon." "Of course," Leah said. The answer sounded like Catherine: composed, useful, unremarkable. Under the table, her left hand tightened around her pen. Executive floor meant the fortieth. It meant private elevators, higher badge scrutiny, and possibly Martha or Richard within the same air. It meant a chance Isabella Thorne could be looked at by people who had known her face since childhood while wearing Catherine Marsh's name and Sterling's clean paperwork like borrowed skin. It also meant proximity. Proximity had been the whole point of coming inside. After the meeting, Marcus leaned over while people gathered their laptops. "First executive briefing?" "At Thorne, yes." "David hates surprises. Give him clean numbers, no unsupported claims, and never let Antonio Costa think you are questioning his portfolio." "Useful warning." Marcus grinned. "Survival advice." Leah returned the smallest possible smile, then carried her laptop back to her desk. By 4:30, Priya's template had arrived: segment overview, growth drivers, regulatory exposure, acquisition history, risk notes. The document gave Catherine permission to look exactly where Leah needed to look. She opened Costa's pharmaceutical R&D files and began cross-checking revenue projections against actual performance. Most of the data behaved. Revenue variance stayed within tolerable ranges. Device margins were ugly but explainable. Diagnostics carried better growth than David's old model suggested. Leah moved line by line, assembling a briefing that would satisfy Priya and give Catherine's searches a legitimate shape. Then a payment label stopped her: Voss Medical Research Foundation - Research Grant. Forty-five thousand dollars. March 2020. Costa Holdings Pharmaceutical R&D. Leah did not move. The office continued around her, bright and ordinary, while the name on her screen pulled every hidden thread tight. Voss, again. She opened the linked record and watched four documents load.